We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioDiscovery and AGRE Enter into a Co-Promotion Agreement
News

BioDiscovery and AGRE Enter into a Co-Promotion Agreement

BioDiscovery and AGRE Enter into a Co-Promotion Agreement
News

BioDiscovery and AGRE Enter into a Co-Promotion Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioDiscovery and AGRE Enter into a Co-Promotion Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioDiscovery, Inc. and the Autism Genetic Resource Exchange (AGRE) have signed a co-promotion agreement. This agreement allows AGRE to provide copy number and allelic event data to its research users through BioDisovery’s Nexus DB platform.

“We are very excited about working with the AGRE consortium,” said Dr. Soheil Shams, President of BioDiscovery, Inc.

Dr. Shams continued, “There has been a tremendous investment in collection and generation of genomic data to better understand Autism and our agreement with AGRE will enable researchers a new way to more easily access and rapidly analyze this data. We hope that the efficient visualization and statistical analysis methods in Nexus Copy Number™ and Nexus DB™ will help to accelerate advancement of research in this very important area.”

“BioDiscovery Nexus Copy Number will allow researchers in our network to easily and quickly navigate through the array data which we make available” said Clara Lajonchere. Ph.D., VP of Clinical Program at Autism Speaks.

Lajonchere continued, “While we have provided our microarray data in other formats and will continue to do so, Nexus DB offers AGRE researchers an efficient and user-friendly interface for viewing and analyzing the thousands of microarray experiments which have been done using the AGRE subjects. Our hope is that this will accelerate the discovery of genes that play a role in autism by simplifying the process of analyzing data.”

BioDiscovery’s software is platform independent and available for Mac OS X, Linux and Windows operating systems.

BioDiscovery Nexus Copy Number is the leading platform independent and user friendly application for DNA copy number analysis.

Nexus Copy Number can integrate and process together, in a single project, data from commercial array platforms such as Agilent, Affymetrix, Illumina, Roche NimbleGen, Next Gen read depth, as well as custom arrays.

With its free access to a web-based repository for querying, and storing genomic data from any location across the globe, Nexus Copy Number is a powerful solution for large groups such as special consortia and collaborative research networks like AGRE.

AGRE is the largest private collection of genotype and phenotype information for over 2,600 individuals with ASD and their family members.

Over the last 15 years, AGRE has amassed an extremely robust clinical dataset that includes detailed medical, developmental, morphological, demographic and behavioral information making it one of the most comprehensive autism family repositories.

There are 350 active researchers from 21 countries that have used the AGRE resource to publish over 202 scientific papers, making it the most widely accessed resource for genetic studies of autism.

Currently, AGRE stores genotyping data for over 1,000 multiplex families using two different microarray analysis platforms, Affimetrix and Illumina, and the availability of those datasets to researchers has been instrumental in moving the field forward.

Advertisement